Cushing's Syndrome - Pipeline Review, Q4 2010

Date: December 1, 2010
Pages: 33
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: C73C163EF0EEN
Leaflet:

Download PDF Leaflet

Cushing's Syndrome - Pipeline Review, Q4 2010
Cushing's Syndrome - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Cushing's Syndrome Pipeline Review, Q4 2010”, provides an overview of the Cushing's Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Cushing's Syndrome , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cushing's Syndrome . “Cushing's Syndrome -Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • A snapshot of the global therapeutic scenario for Cushing's Syndrome   .
  • A review of the Cushing's Syndrome    products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Cushing's Syndrome    pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • A snapshot of the global therapeutic scenario for Cushing's Syndrome   .
  • A review of the Cushing's Syndrome    products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Cushing's Syndrome    pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Introduction
Global Markets Direct Report Coverage
Cushing's Syndrome Overview
Therapeutics Development
An Overview of Pipeline Products for Cushing's Syndrome
Cushing's Syndrome Therapeutics under Development by Companies
Cushing's Syndrome Therapeutics under Investigation by Universities/Institutes
Companies Involved in Cushing's Syndrome Therapeutics Development
Novartis AG
Corcept Therapeutics Incorporated
Samaritan Pharmaceuticals, Inc.
HRA Pharma, SA
Universities/Institutes Involved in Cushing's Syndrome Therapeutics Development
Cushing's Syndrome Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Corlux - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mifedren - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pasireotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SP-6300 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Cabergoline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cushing's Syndrome - Featured News
Sep 22, 2010: Novartis Announces Phase III Trial Results Of SOM230 In Patients With Cushing's Disease
Jul 01, 2010: Corcept Completes Enrollment In Phase III Cushing's Syndrome Study Of CORLUX
Jun 25, 2010: Corcept Nears Completion Of Enrollment In Phase III Cushing’s Syndrome Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Cushing's Syndrome, 2010
Products under Development for Cushing's Syndrome – Comparative Analysis, 2010
Novartis AG, 2010
Corcept Therapeutics Incorporated, 2010
Samaritan Pharmaceuticals, Inc., 2010
HRA Pharma, SA, 2010
Assessment by Monotherapy Products, 2010
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010 22

LIST OF FIGURES

Number of Products under Development for Cushing's Syndrome, 2010
Products under Development for Cushing's Syndrome – Comparative Analysis, 2010
Products under Development by Companies, 2010
Products under Investigation by Universities/Institutes, 2010
Assessment by Monotherapy Products, 2010
Assessment by Route of Administration, 2010
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
Assessment by Stage and Molecule Type, 2010 21
Cushing's Syndrome - Pipeline Review, Q2 2011 US$ 500.00 Apr, 2011 · 46 pages
Cushing's Syndrome – Pipeline Review, H1 2012 US$ 500.00 Apr, 2012 · 42 pages
Acute Coronary Syndrome - Pipeline Review, H2 2014 US$ 2,000.00 Aug, 2014 · 128 pages
Restless Legs Syndrome - Pipeline Review, Q1 2011 US$ 500.00 Mar, 2011 · 41 pages

Ask Your Question

Cushing's Syndrome - Pipeline Review, Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: